## RECEIVED CENTRAL FAX CENTER

NOV 1 2 2008

Application Serial No.: 10/533,371
Amendment and Response dated 11 November 2008

Reply to Office Action of July 11, 2008

Page 3 of 7

wherein said therapeutically effective amount is sufficient to increase the rate of IGPBP-1 expression as to at least increase the rate of liver-damage resolution over the rate of liver-damage progression.

20. (Original) The method according to claim 19 wherein the compound is halofuginone.

21-26. (Canceled)

- 27. (New) The method according to claim 19, wherein said administration specifically activates only hepatocyte cells.
- 28. (New) The method according to claim 19, wherein said administration further induces inhibition of stellate cell mobility.
- 29. (New) A method for improving liver regeneration by increasing the IGFBP-1 expression in hepatocyte cells comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a compound having the formula:

wherein: n=1-2

R<sub>1</sub> is at each occurrence independently selected from the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

R<sub>2</sub> is a member of the group consisting of hydroxy, acetoxy and lower akoxy; and

Application Serial No.: 10/533,371 Amendment and Response dated 11 November 2008 Reply to Office Action of July 11, 2008 Page 4 of 7

R<sub>3</sub> is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof, wherein said administration is performed early in a liver-damaging process.